Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 22, 2026, 1:24 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2041–2064 of 11,977 matching trials from the live ClinicalTrials.gov search.
Conditions
Non-small Cell Lung Cancer
Interventions
PDR001, Cisplatin, Gemcitabine, Pemetrexed, Carboplatin, Paclitaxel, Canakinumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
5
States / cities
Fayetteville, Arkansas • Santa Monica, California • Stanford, California + 2 more
Conditions
Carcinoma of Unknown Primary, Neuroendocrine Carcinoma, Neuroendocrine Carcinoma of the Skin
Interventions
irinotecan hydrochloride
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
New York, New York
Conditions
Small Cell Lung Cancer
Interventions
Amrubicin, Topotecan
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
61
States / cities
Muscle Shoals, Alabama • Tucson, Arizona • Little Rock, Arkansas + 57 more
Conditions
Bronchioloalveolar Cell Variant of Non-small Cell Lung Cancer
Interventions
OSI-774: erlotinib, TarcevaTM
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2013
U.S. locations
1
States / cities
New York, New York
Conditions
Intraabdominal Cancers (Various Types)
Interventions
Cancer Macrobead placement in abdominal cavity
Biological
Lead sponsor
The Rogosin Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
New York, New York
Conditions
Kidney Cancer
Interventions
aldesleukin, sargramostim, vinblastine sulfate
Biological · Drug
Lead sponsor
Hope Cancer Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
2
States / cities
Kansas City, Kansas
Conditions
Estrogen Receptor Positive, HER2/Neu Negative, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Postmenopausal, Progesterone Receptor Positive, Stage I Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
Biopsy of Breast, Copanlisib, Laboratory Biomarker Analysis, Letrozole, Palbociclib, Pharmacological Study
Procedure · Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
19 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Early-Stage Breast Carcinoma
Interventions
Cyrcadia CBR™ device placement for abnormality screening
Device
Lead sponsor
Cyrcadia Health
Industry
Eligibility
21 Years and older · Female only
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
2
States / cities
Mountain View, California • Columbus, Ohio
Conditions
Fallopian Tube Carcinoma, Infectious Disorder, Neutropenia, Ovarian Carcinosarcoma, Primary Peritoneal Carcinoma, Stage III Ovarian Cancer, Stage IV Ovarian Cancer
Interventions
Adjuvant Therapy, Carboplatin, Paclitaxel, Pegfilgrastim
Procedure · Drug · Biological
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
11
States / cities
Orange, California • Iowa City, Iowa • Camden, New Jersey + 6 more
Completed Early Phase 1 Interventional Results available

Vismodegib in Treating Patients With Basal Cell Carcinoma (BCC)

NCT01631331
Conditions
Basal Cell Carcinoma of the Skin, Recurrent Skin Cancer
Interventions
vismodegib, Mohs surgery
Drug · Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Stanford, California
Conditions
Breast Carcinoma, Lymphedema
Interventions
Best Practice, Motivational Interviewing, Quality-of-Life Assessment, Questionnaire Administration
Other · Behavioral
Lead sponsor
City of Hope Medical Center
Other
Eligibility
21 Years and older · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Duarte, California
Conditions
Solid Tumor, Clear Cell Renal Cell Carcinoma, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Neuroendocrine Tumors, MSI-H Cancer, Cancer With A High Tumor Mutational Burden, Extensive-stage Small-cell Lung Cancer
Interventions
23ME-00610
Drug
Lead sponsor
23andMe, Inc.
Industry
Eligibility
12 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
10
States / cities
Palo Alto, California • Atlanta, Georgia • Detroit, Michigan + 7 more
Conditions
Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma, Advanced or Metastatic KRAS-mutant Tumor in Colorectal Cancer, Advanced or Metastatic KRAS-mutant Tumor in Non Small Cell Lung Cancer, Advanced Solid Tumors, Advanced or Metastatic KRAS-mutant Tumor
Interventions
WEF-001
Drug
Lead sponsor
Auricula Biosciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Dallas, Texas • San Antonio, Texas
Conditions
Advanced Cancer, Breast Cancer, Sarcoma, Pancreatic Cancer, Small Cell Lung Cancer, Ovarian
Interventions
Pembrolizumab, Gemcitabine, Docetaxel, Nab-paclitaxel, Vinorelbine, Irinotecan, Liposomal Doxorubicin
Drug
Lead sponsor
Western Regional Medical Center
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
Goodyear, Arizona
Conditions
Stage IIIA Hepatocellular Carcinoma, Stage IIIB Hepatocellular Carcinoma, Stage IIIC Hepatocellular Carcinoma, Stage IVA Hepatocellular Carcinoma, Stage IVB Hepatocellular Carcinoma
Interventions
Laboratory Biomarker Analysis, Nivolumab, Yttrium Y 90 Glass Microspheres
Other · Biological · Radiation
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Terminated Phase 1Phase 2 Interventional Results available

Survival Prolongation by Rationale Innovative Genomics

NCT03386929
Conditions
Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Stage IIIB
Interventions
Avelumab, Axitinib, Palbociclib
Drug
Lead sponsor
Worldwide Innovative Network Association
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
La Jolla, California • Sioux Falls, South Dakota
Conditions
Colon Adenocarcinoma, Colorectal Carcinoma, Rectal Adenocarcinoma
Interventions
Dietary intervention via Text Messaging, Survey Administration, Nutrition Education
Behavioral · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
San Francisco, California
Conditions
Advanced Solid Tumors, Carcinoid, Colorectal Cancer, Locally Advanced, Lymphoma, Metastatic Cancer, Non-Small Cell Lung Cancer, Sarcoma, Solid Tumors
Interventions
Modified FOLFOX6, Conatumumab, Ganitumab, Bevacizumab
Drug · Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
10
States / cities
Duarte, California • La Jolla, California • Denver, Colorado + 7 more
Conditions
Ovarian Carcinoma, Psychiatric Disorder
Interventions
Behavioral Intervention, Interview, Survey Administration
Behavioral · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Genital Neoplasm, Female, Abdominal Neoplasm, Recurrence
Interventions
AB-1015
Biological
Lead sponsor
Arsenal Biosciences, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
8
States / cities
San Francisco, California • Aurora, Colorado • Iowa City, Iowa + 5 more
Conditions
Renal Cell Cancer, Kidney Cancer
Interventions
Sunitinib, Temsirolimus
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Houston, Texas
Conditions
Neoplasms, Colorectal Neoplasms, Melanoma, Pancreatic Neoplasms, Sarcoma, Ovarian Neoplasms, Brain Neoplasms, Thyroid Neoplasms, Neuroendocrine Tumors, Cholangiocarcinoma, Salivary Gland Neoplasms, Head and Neck Neoplasms, Thyroid Cancer, Papillary, Lymphoma, Large-Cell, Anaplastic, Neoplasms by Site, Respiratory Tract Neoplasms, Thoracic Neoplasms, Respiratory Tract Diseases, Carcinoma, Bronchogenic, Bronchial Neoplasms, Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms, Digestive System Diseases, Gastrointestinal Diseases, Colonic Diseases, Intestinal Diseases, Central Nervous System
Interventions
Alectinib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
29
States / cities
Culver City, California • Los Angeles, California • Sacramento, California + 21 more
Completed Early Phase 1 Interventional

STAT3 DECOY in Head and Neck Cancer

NCT00696176
Conditions
Head and Neck Cancer
Interventions
STAT 3 DECOY
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Advanced Malignancies
Interventions
Part A, Part B
Biological
Lead sponsor
TopAlliance Biosciences
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
14
States / cities
Santa Monica, California • Aurora, Colorado • Miami, Florida + 9 more